Oasmia Pharmaceutical AB
OASM
OASM was delisted on the 21st of August, 2019.
3 hedge funds and large institutions have $443K invested in Oasmia Pharmaceutical AB in 2017 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
50% more funds holding
Funds holding: 2 → 3 (+1)
13% less capital invested
Capital invested by funds: $512K → $443K (-$69K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$82.2K |
| 2 |
SCM
Sio Capital Management
New York
|
+$35.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$258 |
Top Sellers
OASM Hedge Fund Activity: Q1 2017 in Review
3 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Oasmia Pharmaceutical AB (OASM) for Q1 2017, worth a combined $443K — down 13% from $512K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new OASM positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $82.2K.
- 3 institutional investors held Oasmia Pharmaceutical AB (OASM) as of Q1 2017, up from 2 in Q4 2016.
- Funds reported $443K of Oasmia Pharmaceutical AB stock for Q1 2017, down 13% quarter-over-quarter.
- 2 funds opened new Oasmia Pharmaceutical AB positions in Q1 2017 and 1 closed out, a net change of +1 holder.
- The largest Oasmia Pharmaceutical AB buyer in Q1 2017 was Sabby Management, an estimated $82.2K added.
Based on aggregated 13F filings for Q1 2017.